IBS--review and what's new.
Irritable bowel syndrome (IBS) is a highly prevalent gastrointestinal motility disorder broadly characterized by abdominal pain/discomfort associated with altered bowel habits. The chronic and bothersome nature of IBS symptoms often negatively affects patient quality of life and activity level and places a substantial economic burden on patients and the healthcare system. Advances in research have led to a greater understanding of the underlying pathophysiology of IBS, particularly regarding the role serotonin plays in the gastrointestinal tract; the development of stepwise, symptom-based diagnostic strategies that allow for a diagnosis of IBS to be made without the need for extensive laboratory testing; and the development of treatment options targeting underlying pathophysiologic mechanisms that provide relief of the multiple symptoms associated with IBS. This review highlights recent advances in research and discusses how these findings can be applied to daily clinical practice.
Foxx-Orenstein
Amy
A
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA. Foxx-Orenstein.Amy@mayo.edu
D001424:Bacterial Infections / Q000150:complications; D004198:Disease Susceptibility; D004777:Environment; D005762:Gastroenterology / Q000639:trends*; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology* / Q000235:genetics; D012701:Serotonin / Q000378:metabolism; D015398:Signal Transduction
D005765:Gastrointestinal Agents; D012701:Serotonin